MX2022007315A - Formulaciones de olanzapina de liberacion sostenida. - Google Patents

Formulaciones de olanzapina de liberacion sostenida.

Info

Publication number
MX2022007315A
MX2022007315A MX2022007315A MX2022007315A MX2022007315A MX 2022007315 A MX2022007315 A MX 2022007315A MX 2022007315 A MX2022007315 A MX 2022007315A MX 2022007315 A MX2022007315 A MX 2022007315A MX 2022007315 A MX2022007315 A MX 2022007315A
Authority
MX
Mexico
Prior art keywords
sustained release
olanzapine formulations
release olanzapine
olanzapine
methods
Prior art date
Application number
MX2022007315A
Other languages
English (en)
Inventor
Mark Alan Smith
Carine Claassen-Punt
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of MX2022007315A publication Critical patent/MX2022007315A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

La presente invención está dirigida a métodos para tratar la esquizofrenia o el trastorno bipolar, administrando por vía subcutánea una forma de dosificación de liberación sostenida de olanzapina, o una sal farmacéuticamente aceptable de la misma. También se describen los métodos para administrar subcutáneamente olanzapina, o una sal farmacéuticamente aceptable de la misma.
MX2022007315A 2015-09-21 2018-03-16 Formulaciones de olanzapina de liberacion sostenida. MX2022007315A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21

Publications (1)

Publication Number Publication Date
MX2022007315A true MX2022007315A (es) 2022-07-13

Family

ID=57047342

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003380A MX2018003380A (es) 2015-09-21 2016-09-21 Formulaciones de olanzapina de liberacion sostenida.
MX2022007315A MX2022007315A (es) 2015-09-21 2018-03-16 Formulaciones de olanzapina de liberacion sostenida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003380A MX2018003380A (es) 2015-09-21 2016-09-21 Formulaciones de olanzapina de liberacion sostenida.

Country Status (22)

Country Link
US (4) US20170079985A1 (es)
EP (2) EP3352735B1 (es)
JP (2) JP2018527397A (es)
KR (1) KR20180054627A (es)
CN (2) CN108289834A (es)
AR (1) AR106085A1 (es)
AU (2) AU2016328958B2 (es)
CA (1) CA2998504C (es)
CL (1) CL2018000727A1 (es)
DK (1) DK3352735T3 (es)
EA (1) EA201890788A1 (es)
ES (1) ES2960753T3 (es)
FI (1) FI3352735T3 (es)
HK (1) HK1255946A1 (es)
HU (1) HUE063850T2 (es)
IL (3) IL295161A (es)
MX (2) MX2018003380A (es)
NZ (1) NZ740665A (es)
PL (1) PL3352735T3 (es)
PT (1) PT3352735T (es)
TW (1) TWI798161B (es)
WO (1) WO2017053346A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
AU752552C (en) * 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1863557B (zh) 2003-06-26 2010-06-16 普西维达公司 原位胶凝的药物递送系统
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
KR101225257B1 (ko) 2004-06-04 2013-01-22 카무러스 에이비 유동성 데포 제제
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
MX2007012103A (es) * 2005-04-13 2007-11-20 Pfizer Prod Inc Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.
EP2397034A1 (en) * 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
MX2009000434A (es) 2006-07-11 2009-01-29 Qps Llc Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos.
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CA2683698C (en) 2007-04-19 2013-09-10 Hyun Hee Kwak A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
AU2009255675B2 (en) 2008-06-03 2014-10-09 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
DK2355853T3 (en) 2008-10-10 2017-03-06 Polyactiva Pty Ltd BIODEGRADABLE POLYMER-BIOACTIVE FRAGMENT CONJUGATES
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
EP2394663B1 (en) 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
SI2658525T1 (en) 2010-12-29 2018-04-30 Medincell Biodegradable Composites for Delivery
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
US20130144250A1 (en) 2011-10-24 2013-06-06 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
HUE050904T2 (hu) 2012-01-23 2021-01-28 Allergan Inc Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
RU2658004C2 (ru) 2013-06-20 2018-06-19 Фарматен С.А. Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
PT3352735T (pt) 2023-10-30
JP2018527397A (ja) 2018-09-20
US20240238307A1 (en) 2024-07-18
US20180264001A1 (en) 2018-09-20
CL2018000727A1 (es) 2018-09-28
EA201890788A1 (ru) 2018-09-28
CA2998504A1 (en) 2017-03-30
AU2016328958A1 (en) 2018-04-05
TWI798161B (zh) 2023-04-11
PL3352735T3 (pl) 2024-01-29
JP2021167331A (ja) 2021-10-21
IL275735A (en) 2020-08-31
IL295161A (en) 2022-09-01
US20220323458A1 (en) 2022-10-13
CN116942677A (zh) 2023-10-27
CA2998504C (en) 2023-06-20
FI3352735T3 (fi) 2023-10-20
EP4331570A1 (en) 2024-03-06
AU2022206695A1 (en) 2022-08-11
CN108289834A (zh) 2018-07-17
ES2960753T3 (es) 2024-03-06
NZ740665A (en) 2023-04-28
TW201726144A (zh) 2017-08-01
IL258086A (en) 2018-05-31
US20170079985A1 (en) 2017-03-23
HUE063850T2 (hu) 2024-02-28
HK1255946A1 (zh) 2019-09-06
WO2017053346A1 (en) 2017-03-30
EP3352735A1 (en) 2018-08-01
KR20180054627A (ko) 2018-05-24
AR106085A1 (es) 2017-12-13
EP3352735B1 (en) 2023-08-30
AU2016328958B2 (en) 2022-04-21
DK3352735T3 (da) 2023-10-30
MX2018003380A (es) 2018-08-16

Similar Documents

Publication Publication Date Title
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2018004664A (es) Antagonistas de ep4.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2021008738A (es) Regimenes de dosificacion de melflufen para cancer.
EA201992832A1 (ru) Подкожное введение adamts13
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically